ArticleNature2022
ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 281 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
281citing papers in PubMed, 1 pooled it
30.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
281 citing papers in PubMed, 1 synthesis or guideline pooled it, 369 citations in OpenAlex.
- The romantic history of signaling pathway discovery in cell death: an updated review.Molecular and cellular biochemistry · 2024Pooled it
- Biological consequences of Z-nucleic acid sensing by ZBP1 and ADAR1.RNA biology · 2026Review
- Mechanisms, regulation and clinical relevance of necroptosis.Nature reviews. Molecular cell biology · 2026Review
- Exosomal let-7c-5p From AMI Patient Plasma Modulates Neuronal PANoptosis via ZBP1 In Vitro.Cell biochemistry and function · 2026Article
- Article
- Tumour-associated dsRNA accumulation and innate immune activation: mechanistic basis and therapeutic strategies.EBioMedicine · 2026Review
- Viral mimicry escape as a necessary feature of malignant transformation.Nature reviews. Cancer · 2026Review
- Human ZBP1 is a potent inducer of cell death through mechanisms divergent from mouse ZBP1.EMBO reports · 2026Article
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- Genome-wide DNA methylation profiling of triple-negative breast cancer uncovers epigenetic biomarkers of tumor identity and the immune microenvironment.NPJ breast cancer · 2026Article
- Targeting ADAR1 in Cancer: Biology, Therapeutic Strategies, Challenges, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Z-Nucleic Acids: A Regulator of Macrophage PANoptosis and Fungal Biofilm in Fungal Keratitis.Investigative ophthalmology & visual science · 2026Article
- Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer.Advanced healthcare materials · 2026Article
- Structural and molecular principles of DAMP biology.Nature structural & molecular biology · 2026Review
- SUMOylation enhances DNMT1 function to repress mega-intergenic RNAs and viral mimicry.Nature genetics · 2026Article
- Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma.International journal of molecular sciences · 2026Article
- PANoptosis in the pathogenesis of myelodysplastic syndromes.Molecular oncology · 2026Review
- PANoptosis in life and death across cell types: From innate immunity to therapeutic implications.Cell chemical biology · 2026Review
- Spermine suppressesmBio · 2026Article
- Adaptable Covalent Organic Framework-Hydrogel Microneedles for Glucose-Responsive Isoliquiritigenin Delivery in Diabetic Wound Therapy.Advanced healthcare materials · 2026Article
221 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 7 institutions in 5 countries.
Ting Zhang *Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8645-581X
Chaoran Yin *Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Aleksandr Fedorov *Laboratory of Bioinformatics, Faculty of Computer Science, National Research University Higher School of Economics, Moscow, Russia.ORCID http://orcid.org/0000-0002-8829-3447
Liangjun QiaoCollege of Basic Medicine, Chongqing Medical University, Chongqing, China.
Hongliang BaoDivision of Chemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan.ORCID http://orcid.org/0000-0002-0680-4427
Nazar BeknazarovLaboratory of Bioinformatics, Faculty of Computer Science, National Research University Higher School of Economics, Moscow, Russia.
Shiyu WangDivision of Chemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan.
Avishekh GautamBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Riley M WilliamsBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Jeremy Chase CrawfordDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-4096-6048
Suraj PeriBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Vasily StuditskyCancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7389-7993
Amer A BegDepartment of Immunology and Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Paul G ThomasDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7955-0256
Carl WalkleyCancer & RNA Biology, St Vincent's Institute for Medical Research and Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.ORCID http://orcid.org/0000-0002-4784-9031
Yan XuDivision of Chemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan.
Maria PoptsovaLaboratory of Bioinformatics, Faculty of Computer Science, National Research University Higher School of Economics, Moscow, Russia.
Alan HerbertLaboratory of Bioinformatics, Faculty of Computer Science, National Research University Higher School of Economics, Moscow, Russia. alan.herbert@insideoutbio.com.ORCID http://orcid.org/0000-0002-0093-1572
Siddharth BalachandranBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Siddharth.balachandran@fccc.edu.ORCID http://orcid.org/0000-0003-2084-1803
Fox Chase Cancer Center · USNational Research University Higher School of Economics · RUUniversity of Miyazaki · JPSt. Jude Children's Research Hospital · USChongqing Medical University · CNMoffitt Cancer Center · USSt Vincent's Hospital Melbourne · AU
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8MMechanism, Function, and Exploitation of Influenza A Virus-Activated Cell DeathR01AI135025 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2017 to 2025
$6.8MDYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9MTargeting RIPK3 in Flu-Associated Lung InjuryR01AI144400 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2019 to 2023
$3.6MSmall-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapyR01CA269975 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI SIDDHARTH BALACHANDRAN, VASILY M STUDITSKY · 2023 to 2026
$3.0MRIP1/3 Kinases as New Targets in Malignant MesotheliomaR01CA190542 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, TESTA, JOSEPH R. · 2015 to 2019
$2.1MInterferon Activated Necroptosis as a New Therapeutic Avenue for Kidney CancerR01CA168621 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2014 to 2018
$1.9MMechanism of yFACT Action during Chromatin TranscriptionR01GM119398 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI STILLMAN, DAVID J, STUDITSKY, VASILY M · 2017 to 2020
$1.3MMedical Research CouncilNCI NIH HHS P30 CA006927NCI NIH HHS R01 CA168621NCI NIH HHS R01 CA190542NCI NIH HHS R01 CA269975NIAID NIH HHS R01 AI135025NIAID NIH HHS R01 AI144400NIAID NIH HHS U01 AI150747NIGMS NIH HHS R01 GM119398
Abstract
Only a small proportion of patients with cancer show lasting responses to immune checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an emerging determinant of resistance to ICB therapy and prevents ICB responsiveness by repressing immunogenic double-stranded RNAs (dsRNAs), such as those arising from the dysregulated expression of endogenous retroviral elements (EREs)
Indexed as
Adenosine DeaminaseNecroptosisNeoplasmsRNA-Binding Proteins3' Untranslated RegionsAnimalsCancer-Associated FibroblastsCarbazolesHumansImmunotherapyInterferonsMelanomaMiceRNA, Double-Stranded3' Untranslated RegionsADAR1 protein, mouseADAR protein, humanAdenosine DeaminaseCarbazolesCBLC137InterferonsRNA-Binding ProteinsRNA, Double-StrandedZBP1 protein, humanZbp1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.